BR112014005839A2 - composições e métodos para tratamento do câncer usando inibidor da pi3k? e inibidor do caminho da mapk, incluindo inibidores da mek e da raf - Google Patents

composições e métodos para tratamento do câncer usando inibidor da pi3k? e inibidor do caminho da mapk, incluindo inibidores da mek e da raf

Info

Publication number
BR112014005839A2
BR112014005839A2 BR112014005839A BR112014005839A BR112014005839A2 BR 112014005839 A2 BR112014005839 A2 BR 112014005839A2 BR 112014005839 A BR112014005839 A BR 112014005839A BR 112014005839 A BR112014005839 A BR 112014005839A BR 112014005839 A2 BR112014005839 A2 BR 112014005839A2
Authority
BR
Brazil
Prior art keywords
inhibitor
compositions
methods
mapk pathway
raf inhibitors
Prior art date
Application number
BR112014005839A
Other languages
English (en)
Portuguese (pt)
Inventor
Virone-Oddos Angela
Garcia-Echeverria Carlos
Vincent Loïc
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014005839(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112014005839A2 publication Critical patent/BR112014005839A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014005839A 2011-09-16 2012-09-14 composições e métodos para tratamento do câncer usando inibidor da pi3k? e inibidor do caminho da mapk, incluindo inibidores da mek e da raf BR112014005839A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306172A EP2570127A1 (en) 2011-09-16 2011-09-16 Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
PCT/EP2012/068072 WO2013037943A1 (en) 2011-09-16 2012-09-14 Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors

Publications (1)

Publication Number Publication Date
BR112014005839A2 true BR112014005839A2 (pt) 2017-03-28

Family

ID=46851503

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005839A BR112014005839A2 (pt) 2011-09-16 2012-09-14 composições e métodos para tratamento do câncer usando inibidor da pi3k? e inibidor do caminho da mapk, incluindo inibidores da mek e da raf

Country Status (26)

Country Link
US (1) US20140275078A1 (cg-RX-API-DMAC10.html)
EP (2) EP2570127A1 (cg-RX-API-DMAC10.html)
JP (1) JP2014530181A (cg-RX-API-DMAC10.html)
KR (1) KR20140062143A (cg-RX-API-DMAC10.html)
CN (1) CN103889418A (cg-RX-API-DMAC10.html)
AR (1) AR087902A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012307309A1 (cg-RX-API-DMAC10.html)
BR (1) BR112014005839A2 (cg-RX-API-DMAC10.html)
CA (1) CA2847091A1 (cg-RX-API-DMAC10.html)
CL (1) CL2014000606A1 (cg-RX-API-DMAC10.html)
CO (1) CO6910192A2 (cg-RX-API-DMAC10.html)
CR (1) CR20140102A (cg-RX-API-DMAC10.html)
DO (1) DOP2014000046A (cg-RX-API-DMAC10.html)
EA (1) EA201490638A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP14013244A (cg-RX-API-DMAC10.html)
GT (1) GT201400038A (cg-RX-API-DMAC10.html)
IL (1) IL231212A0 (cg-RX-API-DMAC10.html)
MA (1) MA35615B1 (cg-RX-API-DMAC10.html)
MX (1) MX2014003223A (cg-RX-API-DMAC10.html)
NI (1) NI201400020A (cg-RX-API-DMAC10.html)
PE (1) PE20141035A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014500536A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201400380XA (cg-RX-API-DMAC10.html)
TN (1) TN2014000086A1 (cg-RX-API-DMAC10.html)
UY (1) UY34341A (cg-RX-API-DMAC10.html)
WO (1) WO2013037943A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9913844B2 (en) 2013-03-21 2018-03-13 Novartis Ag Combination therapy
US20160030440A1 (en) * 2013-04-05 2016-02-04 Sanofi Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor
WO2015051252A1 (en) * 2013-10-03 2015-04-09 Duke University Compositions and methods for treating cancer with jak2 activity
WO2015161230A1 (en) * 2014-04-19 2015-10-22 Massachusetts Institute Of Technology Methods of reducing kinase inhibitor resistance
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
KR101950094B1 (ko) 2017-07-28 2019-02-19 이성재 보릿대 공예품 제작방법
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
CN120204228B (zh) * 2025-04-17 2026-01-30 重庆医科大学附属第一医院 化合物或其盐在制备癌症治疗药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
FR2951169B1 (fr) * 2009-10-09 2011-12-02 Sanofi Aventis Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
PE20120640A1 (es) 2009-07-02 2012-06-09 Sanofi Sa Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)

Also Published As

Publication number Publication date
EA201490638A1 (ru) 2014-08-29
CA2847091A1 (en) 2013-03-21
JP2014530181A (ja) 2014-11-17
EP2755653A1 (en) 2014-07-23
MA35615B1 (fr) 2014-11-01
TN2014000086A1 (en) 2015-07-01
AR087902A1 (es) 2014-04-23
ECSP14013244A (es) 2014-07-31
IL231212A0 (en) 2014-04-30
WO2013037943A8 (en) 2013-07-18
CN103889418A (zh) 2014-06-25
NI201400020A (es) 2014-04-23
CR20140102A (es) 2014-05-07
AU2012307309A1 (en) 2014-04-03
US20140275078A1 (en) 2014-09-18
WO2013037943A1 (en) 2013-03-21
UY34341A (es) 2013-04-05
EP2570127A1 (en) 2013-03-20
KR20140062143A (ko) 2014-05-22
PH12014500536A1 (en) 2019-08-07
MX2014003223A (es) 2014-06-05
CL2014000606A1 (es) 2014-11-07
CO6910192A2 (es) 2014-03-31
DOP2014000046A (es) 2014-07-15
SG11201400380XA (en) 2014-04-28
GT201400038A (es) 2014-12-16
PE20141035A1 (es) 2014-09-04

Similar Documents

Publication Publication Date Title
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
BR112013020798A2 (pt) terapia de combinação do inibidor mtor /jak
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
TR201816379T4 (tr) DNA-PK inhibitörleri.
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
MX386489B (es) Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
CR20150217A (es) Inhibidores de histona demetilasas
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
BR112015029970A2 (pt) inibidores de cinase
BR112013029640A2 (pt) derivados de piridina e pirazina
MX2017016322A (es) Metodos para tratar tumores de celulas epitelioides.
ECSP14030779A (es) Inhibidores del nampt
MX2016001446A (es) Inhibidores de heterobicicloaril rorc2 y metodos de uso de los mismos.
CU20150091A7 (es) Estra-1, 3,5(10), 16tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
NI201400020A (es) COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
BR112014004577A2 (pt) inibidor pi3k para uso no tratamento de câncer ósseo ou para prevenção por metástase de células cancerosas primárias para os ossos
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
BR112013033836A2 (pt) terapia de combinação
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
BR112014030992A2 (pt) composições compreendendo calcogenetos e métodos relacionados
EA201501177A1 (ru) Фармацевтические композиции

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]